Hämatrain - Effects of hybrid movement therapy on physical and psychological parameters during inpatient and outpatient hematological treatment

Hämatrain - Effects of hybrid movement therapy on physical and psychological parameters during inpatient and outpatient hematological treatment - Hämatrain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00034396

Enrollment

Registered

2024-06-07

Start date

2022-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C81.0 C91.0

Interventions

Group 1: At the beginning of their hospitalisation, patients are introduced to the online training platform and a personalised training plan is drawn up. The content of the introductory training (1:1)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Haematological disease treated with drug-based tumour therapy Treatment with a first-line therapy (first-line therapy)

Exclusion criteria

Exclusion criteria: Serious cardiac diseases (e.g. heart failure NYHA III, myocardial infarction III Severe pulmonary global insufficiency Renal insufficiency (GFR 3mg/dl) Severe neurological disorders No access to independent exercise therapy due to lack of technical skills (no e-mail address etc.) Thrombocytopenia below 10,000/µl

Design outcomes

Primary

Measure	Time frame
muscle strength: manual force measurement cardiac performence: ergometry (WHO-Scheme) The time until the first complete remission is achieved serves as a run-in phase in which patients receive two supervised training sessions in the first week. After achieving the first complete remission (CR), the first measurement is carried out, in which strength, endurance, quality of life and fatigue are determined with the help of tests and standardised questionnaires. A second measurement takes place 12 weeks after achieving the first complete remission, during which the patients complete the training programme twice a week on their own.	—

Measure

Time frame

muscle strength: manual force measurement cardiac performence: ergometry (WHO-Scheme) The time until the first complete remission is achieved serves as a run-in phase in which patients receive two supervised training sessions in the first week. After achieving the first complete remission (CR), the first measurement is carried out, in which strength, endurance, quality of life and fatigue are determined with the help of tests and standardised questionnaires. A second measurement takes place 12 weeks after achieving the first complete remission, during which the patients complete the training programme twice a week on their own.

—

Secondary

Measure	Time frame
quality of life: EORTC Questionnaire fatigue: MFI-20 Questionnaire The time until the first complete remission is achieved serves as a run-in phase in which patients receive two supervised training sessions in the first week. After achieving the first complete remission (CR), the first measurement is carried out, in which strength, endurance, quality of life and fatigue are determined with the help of tests and standardised questionnaires. A second measurement takes place 12 weeks after achieving the first complete remission, during which the patients complete the training programme twice a week on their own.	—

Measure

Time frame

quality of life: EORTC Questionnaire fatigue: MFI-20 Questionnaire The time until the first complete remission is achieved serves as a run-in phase in which patients receive two supervised training sessions in the first week. After achieving the first complete remission (CR), the first measurement is carried out, in which strength, endurance, quality of life and fatigue are determined with the help of tests and standardised questionnaires. A second measurement takes place 12 weeks after achieving the first complete remission, during which the patients complete the training programme twice a week on their own.

—

Countries

Germany

Contacts

Public ContactThorsten Schmidt

Universitäres Cancer Center Schleswig-Holstein

thorsten.schmidt@uksh.de0431-50018522

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 6, 2026